Carfilzomib for the Prevention of Graft Versus Host Disease
Status:
Unknown status
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety and efficacy of Carfilzumib, which is a novel
biological agent used in the treatment of multiple myeloma in preventing graft-versus-host
disease, after stem cells transplantation from unrelated donors.